Sementis is an Australian unlisted public biotechnology company that is using its proprietary SCV platform.
The Company is using its proprietary Sementis Copenhagen Vector (SCV) platform technology to generate a portfolio of innovative vaccine candidates for the prevention of allergies and infectious diseases. SCV is a novel vector platform that uses a replication-incompetent vaccinia virus to stimulate both B-cell and T-cell immune responses. The genes for disease antigens are added to the SCV, which upon inoculation elicits a potent immune response to the disease state.
The Company’s product development strategy initially focuses on the development of a therapeutic peanut hypo-allergy vaccine for the treatment for peanut allergy and a Chikungunya preventative (prophylactic) vaccine.
The technology has broad applications which can potentially lead to partnerships involving license fees based on achieving milestones and royalties.